Posted by Michael Wonder on 20 Oct 2022
Drug makers look to limit Medicare’s new power to negotiate lower drug prices
20 October 2022 - Industry tries to ease impact of Inflation Reduction Act, as regulators start to implement the law.
Drugmakers are trying to blunt Medicare’s newfound power to negotiate medicine prices while coping with internal industry disputes and ebbing influence in Washington, D.C.
